foxo4 dri senolytic peptide human trial 2024 2025 PDF) The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI Senolytic Interventions for Type 2
Description
Retrieved from Novo Nordisk-c
Cognitive enhancement effects persist for weeks after the peptide clears from circulation because dihexa initiates structural neuroplasticity changes that continue independently
This design minimises bias and provides the most reliable evidence of treatment efficacy
They enrolled Liam in the trial
Maintenance therapy: Every 24 weeks for ongoing energy, mental clarity, and nutrient support
